Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of combination of APOE inhibitor and PD-1 monoclonal antibody in preparation of medicine for treating gastrointestinal tumors

A technology of digestive tract tumor and PD-1, applied in the field of medicine, can solve the problem of low effective rate and achieve the effect of improving the effective rate of treatment

Active Publication Date: 2021-11-05
JIANGSU PROVINCE HOSPITAL THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIV
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The purpose of the present invention is to solve the problem of low efficiency of PD-1 monoclonal antibody in the treatment of gastrointestinal tumors in the prior art, and to provide APOE inhibitors combined with PD-1 monoclonal antibodies in the preparation of drugs for the treatment of gastrointestinal tumors It has been proved by experiments that the combination of APOE inhibitor and PD-1 monoclonal antibody can further inhibit gastrointestinal tumors and improve the effective rate of treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of APOE inhibitor and PD-1 monoclonal antibody in preparation of medicine for treating gastrointestinal tumors
  • Application of combination of APOE inhibitor and PD-1 monoclonal antibody in preparation of medicine for treating gastrointestinal tumors
  • Application of combination of APOE inhibitor and PD-1 monoclonal antibody in preparation of medicine for treating gastrointestinal tumors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Establishment of wild-type mouse C57BL / 6 subcutaneous liver cancer, intestinal cancer, gastric cancer xenograft model

[0017] C57BL / 6 mice (purchased from Weitong Lihua), 4 weeks old, cell lines (MC38-intestinal cancer, Hepa1-6-liver cancer, MFC-gastric cancer, all purchased from Shanghai Institute of Cell Biology, Chinese Academy of Sciences), using Subcutaneous liver cancer, intestinal cancer, and gastric cancer xenograft models were established by injection in the groin. The specific method is as follows: select cells with good growth status (MC38-intestinal cancer, Hepa1-6-liver cancer or MFC-gastric cancer cells), pour out the culture medium in the bottle, add 2ml of D-Hanks solution, shake it gently, pour it into Add 0.25% trypsin and O.02% EDTA mixed (1:1) 3ml of digestion solution into the bottle, gently shake the culture bottle to make the digestion solution flow over all cell surfaces, and digest at room temperature 25°C for 3 minutes. Observe under an inver...

Embodiment 2

[0019] Combination of APOE inhibitor and PD-1 monoclonal antibody in the treatment of gastrointestinal tumors

[0020] 1. Take liver cancer transplanted tumor model mice and divide them into four groups, which are set as control group, PD1 monoclonal antibody group (αPD-1), COG133TFA monotherapy group (αAPOE), PD1 monoclonal antibody and COG133TFA combined group (αAPOE+ αPD-1), 4 mice in each group, and the four groups of mice were treated according to the corresponding groups. Among them, the PD1 monoclonal antibody group: intraperitoneal injection of 6.6mg / kg on the eighth day, and then injected every three days ; COG133TFA single use group: intraperitoneal injection of 1 mg / kg on the second day, and then once every five days; PD1 monoclonal antibody and COG133TFA combined group: intraperitoneal injection of COG133TFA 1 mg / kg on the second day, and then every five days Inject PD1 monoclonal antibody 6.6mg / kg intraperitoneally for eight days, and inject once every three days ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of combination of an APOE inhibitor and a PD-1 monoclonal antibody in preparation of a medicine for treating gastrointestinal tumors and belongs to the technical field of medicines. Through researches, inventors find that compared with the prior art that the PD-1 monoclonal antibody is used for treating the gastrointestinal tumors, the combination of the APOE inhibitor and the PD-1 monoclonal antibody can be used for further inhibiting the gastrointestinal tumors and improving the effective rate of treatment, and the combination has an important significance in treatment on the gastrointestinal tumors especially for patients with low sensitivity to treatment of the PD-1 monoclonal antibody.

Description

technical field [0001] The invention relates to the application of an APOE inhibitor combined with a PD-1 monoclonal antibody in the preparation of a drug for treating digestive tract tumors, and belongs to the technical field of medicine. Background technique [0002] Gastrointestinal tumor is one of the most common malignant tumors in my country. Its incidence rate is increasing year by year, and the age of onset tends to be younger, which seriously threatens people's health and life. Due to the particularity and complexity of the etiology and pathogenesis of gastrointestinal tumors, the clinical cure rate is low, and the effective rate of targeted therapy and immunotherapy is about 20%, so it is extremely important to improve the effective rate. [0003] At present, the effective rate of PD-1 monoclonal antibody for the treatment of gastrointestinal tumors is 15-20%, which is relatively low. Anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies all depend on their expression o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K38/17A61K39/395A61P35/00A61P1/00
CPCA61K45/06A61K38/17A61K39/3955A61P35/00A61P1/00A61K2039/505A61K2300/00
Inventor 王学浩唐薇薇刘力惠冰清卢琛荣大伟
Owner JIANGSU PROVINCE HOSPITAL THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com